Examining how the brain clears amyloid-β in Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the mechanisms behind the accumulation and clearance of amyloid-β (Aβ) deposits in the brain, particularly focusing on the role of the blood-brain barrier and the glymphatic system. Participants with subjective cognitive decline, mild cognitive impairment, and mild Alzheimer's disease will undergo detailed clinical assessments, including MRI and PET imaging, to better understand the interactions affecting Aβ removal. The study aims to develop a mechanistic model of Aβ clearance that could inform future therapeutic strategies. Follow-up assessments are planned for a subsequent study pending funding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of amnestic MCI or AD dementia or clinical normal
* Able to provide written informed consent
* Unchanged pharmacotherapy within 4 days prior to the study specific assessments
* Fluent in German

Exclusion Criteria:

* Unable to give informed consent or has a legal guardian
* Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
* Clinically relevant depression
* Acute suicidality
* Current alcohol, drug or medication abuse
* History of severe traumatic brain injury within 3 months prior to inclusion
* Structural lesions of the basal ganglia or brain stem
* Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
* Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension
* Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication
* Renal failure \> stage 3 (GFR \< 30 mL/min)
* Pregnancy
* Unresolved malignancies within two years prior to inclusion
* Severe current infections or other chronic or systemic disorders
* Other circumstances which preclude participation based on the investigator's judgement

Where it's running

• Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
  München, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Robert Perneczky, Prof.Dr.med. — Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
• Study coordinator: Robert Perneczky, Prof.Dr.med.
• Email: PSY.Alzheimerzentrum@med.uni-muenchen.de
• Phone: +4989440055863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice

  This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.

  Recruiting Fudan University · Shanghai, Jingan · NCT07923812

• Automated language analysis to help diagnose neurodegenerative diseases

  A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Bari · NCT07906769

• LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment

  A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07866768

• Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement

  This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.

  Recruiting University Hospital, Akershus · Prague · NCT07842146

• Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease

  This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07803055

• Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases

  This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07798700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.